ADC Therapeutics
ADCT
86 hedge funds and large institutions have $182M invested in ADC Therapeutics in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 40 reducing their positions, and 10 closing their positions.
136% more capital invested
Capital invested by funds: $77.3M → $182M (+$105M)
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
13.17% more ownership
Funds ownership: 55.34% → 68.52% (+13%)
5% more funds holding
Funds holding: 82 → 86 (+4)
30% less call options, than puts
Call options by funds: $203K | Put options by funds: $291K
60% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.3M |
| 2 |
HCM
Heights Capital Management
San Francisco,
California
|
+$5.96M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.77M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$1.95M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$837K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$1.37M |
| 2 |
BlackRock
New York
|
-$825K |
| 3 |
VCG
Vantage Consulting Group
Virginia Beach,
Virginia
|
-$353K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$233K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$215K |
ADCT Hedge Fund Activity: Q2 2025 in Review
86 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q2 2025, worth a combined $182M — up 136% from $77.3M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ADCT positions and 10 closed out — a net gain of 4 holders — while 16 added to existing stakes and 40 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $16.3M. The largest seller was Platinum Investment Management, cutting an estimated $1.37M.
- 86 institutional investors held ADC Therapeutics (ADCT) as of Q2 2025, up from 82 in Q1 2025.
- Funds reported $182M of ADC Therapeutics stock for Q2 2025, up 136% quarter-over-quarter.
- 14 funds opened new ADC Therapeutics positions in Q2 2025 and 10 closed out, a net change of +4 holders.
- The largest ADC Therapeutics buyer in Q2 2025 was Point72 Asset Management, an estimated $16.3M added.
- The largest ADC Therapeutics seller in Q2 2025 was Platinum Investment Management, an estimated $1.37M sold.
Based on aggregated 13F filings for Q2 2025.